Independent Director

Robert E. Hayes

Audit Committee Chair · Public Markets · Governance Counsel

Thirty-two years as an operator, finance executive, and independent director — the last fourteen on the boards of NYSE- and Nasdaq-listed companies in industrials, financials, and consumer health.

CurrentlyThree public boards
SpecialtyAudit Chair · ESG
ResidentGreenwich, CT
Profile

I have served on fourteen boards of directors over the last two decades — twelve as an independent director, five as the chair of audit, two as lead independent director. I came to the boardroom from the CFO seat at a Fortune 500 industrial, where I served for nine years.

My boards have together navigated five activist campaigns, three CEO transitions, two restatements, a hostile takeover, and a global financial crisis. I have a measured but firm view of what good governance looks like — and a sometimes-unpopular view of when companies confuse it with theatre.

I take new board seats sparingly. I will not chair more than two audit committees at a time. I do not sit on the boards of competing companies. Personal capacity, in this work, is not optional.

Board Service

Current and recent directorships.

Three current public-company seats. Three concluded in the last decade. Confidential and not-for-profit boards omitted by preference.

2024 – present
Helix Bio · NYSE: HLX
Independent Director · Chair, Audit Committee. Joined post-IPO to professionalize the finance committee and lead the first three quarterly reporting cycles as a public company.
Active · Audit Chair
2020 – present
Atlas Industrials · NYSE: ATL
Independent Director · Member of the Audit and Compensation Committees. Three CEO transitions, one strategic review.
Active
2018 – present
Northbridge Financial · Nasdaq: NBFL
Lead Independent Director · Chair, Risk Committee. Mid-cap commercial lender; led the board through the 2023 banking-sector dislocation.
Active · Lead Director
2014 – 2023
Cedarstone Group · NYSE: CDR
Independent Director · Chair, Audit Committee. Stepped off after nine years and the completion of the spin-off transaction.
Concluded
2012 – 2020
Greenfield Health · NYSE: GFH
Independent Director. Two CEO transitions; one defended activist campaign; one divestiture.
Concluded
Areas of Practice

Where the work concentrates.

i.

Audit Committee Chair

SOX compliance, auditor relationships, restatement risk, internal controls, audit-quality engagement. Most boards underweight this function until they cannot.

ii.

CEO Transition Counsel

Five CEO transitions in the last decade. Search committee leadership, succession discipline, the difficult conversations the rest of the board would rather avoid.

iii.

Activism & Shareholder Action

Three defended campaigns. Calm engagement with shareholders is almost always better than the alternative — and the alternative is almost always available too late.

iv.

Risk & ESG Governance

Building credible risk frameworks for boards that have grown beyond their original committee structures. ESG that is auditable rather than rhetorical.

v.

Public-Market Readiness

Pre-IPO board construction, S-1 preparation from the audit perspective, the institutional muscle the first public board needs to build before listing.

vi.

Strategic Review & M&A

Independent committee leadership through strategic alternatives, including divestitures, take-privates, and contested transactions.

Robert is the director every CEO secretly wants and most board chairs quietly need. He asks the question two meetings before everyone else thinks to.
— Sir Andrew Lockhart Chair, Northbridge Financial
Credentials & Education

A condensed professional record.

EducationHarvard MBA '92
Princeton AB '88
LicensesCPA · CGMA
Director Cert.NACD Fellow
CounselSullivan & Cromwell (ret. partner spouse)
Boards3 active · 14 total
CivicMet Museum · Council on Foreign Relations

Selected operating roles

  • Chief Financial Officer · Cedarstone GroupNine years; oversaw three M&A transactions and the 2008 capital-restructuring.
  • Senior Vice President · Procter & GambleIndustrial supply chain; led the European turnaround following the 2001 reorganization.
  • Partner · McKinsey & CompanyIndustrial Practice; New York and London offices; partner from 1998.
  • Associate · Goldman Sachs · Industrials CoverageMergers and acquisitions; client coverage in chemicals and capital goods.
Inquiries

For board enquiries, kindly write.

I review new board approaches once a quarter. Search-firm enquiries are best directed to my assistant; direct approaches from chairs or lead directors will receive a personal reply within ten days.

Write to R. E. Hayes